| Date | Title | Description |
| 24.07.2026 | Crystalys Therapeutics Announces $130 Million Series B Financing To Advance Gout Treatment Dotinurad | Crystalys Therapeutics announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 in... |
| 22.07.2026 | Crystalys Therapeutics Raises $130 Million To Bring Late-Stage Gout Drug To U.S. Market | Crystalys Therapeutics raises $130 million in an oversubscribed Series B financing round. The funding will help Crystalys take its late-stage gout drug to market. Series B comes less than a year after its impressive $205 million Series A of... |
| 17.07.2026 | DIMERIX EXPANDS PIPELINE WITH ACQUISITION OF PHASE 2 READY ASSET FOR ACUTE KIDNEY INJURY | Highlights
Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI)
DMX-6... |
| 14.07.2026 | Draig Therapeutics Closes $65 Million Series B To Advance AMPA And GABAA Receptor Modulators In Neuropsychiatric Disorders | Draig Therapeutics, a clinical-stage biopharmaceutical company co-founded by Cardiff University and SV Health Investors and headquartered across Newton, Massachusetts and Cardiff, United Kingdom, has closed an oversubscribed $65 million Ser... |
| 14.07.2026 | FORE Biotherapeutics Inks $67.4 Million Series D-2 Extension |
PHILADELPHIA, PA, FORE Biotherapeutics, a company dedicated to developing targeted therapies to treat patients with cancer, announced the closing of an upsized Series D-2 extension financing of $67.4 million.
>> Click here for more f... |
| 14.07.2026 | Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric Therapies | Draig Therapeutics announced the closing of an oversubscribed $65 million Series B financing to accelerate development of its pipeline of neuropsychiatric therapies. The round was led by new investor Deep Track Capital, with participation f... |
| 11.07.2026 | FORE Biotherapeutics Secures $110M Total Funding for Groundbreaking BRAF Cancer Drug | FORE Biotherapeutics secured $67.4 million, completing its Series D-2 funding at $110 million. This capital fuels plixorafenib, a next-generation BRAF inhibitor. The drug targets challenging BRAF-altered cancers, including primary CNS tumor... |
| 10.07.2026 | FORE Biotherapeutics Raises $67.4 Million In Series D-2 Extension To Advance Plixorafenib | FORE Biotherapeutics, a registration-stage oncology company focused on targeted cancer therapies, announced the closing of an upsized $67.4 million Series D-2 extension financing, bringing the total raised in the Series D-2 round to $110 mi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M to Advance BRAF Cancer Therapy | FORE Biotherapeutics Expands Funding for Late-Stage Cancer Program
FORE Biotherapeutics has raised $67.4 million to support the development of its lead targeted cancer therapy, plixorafenib. The round was co-led by SR One, Medicxi, SymBiosi... |
| 08.07.2026 | FORE Biotherapeutics Raises $67.4M in Series D-2 Extension Funding | Fore Biotherapeutics, a Philadelphia, PA-based registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, raised $67.4M in Series D-2 extension funding.
The round was led by SR One, ... |
| 06.05.2026 | Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline | Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, S... |
| 05.05.2026 | Windward Bio secures USD 165 million to advance clinical trials |
WIN378, Windward's lead program, is a next-generation, fully human monoclonal antibody that potently binds to the thymic stromal lymphopoietin (TSLP) ligand. This well-validated cytokine plays a key role in the development and progression ... |
| 04.03.2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding.
The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| 03.03.2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| 26.01.2026 | Corxel Raises Up to $287 Million In Series D1 To Advance Oral GLP 1 Program and Broader Cardiometabolic Pipeline | CORXEL Pharmaceuticals Limited said it has completed a Series D1 financing, raising up to $287 million to fund the development of CX11, its oral small molecule GLP-1 receptor agonist for obesity and overweight, as well as additional cardiom... |
| 26.01.2026 | Corxel Pharmaceuticals Raises $287M in Series D1 Funding | Corxel Pharmaceuticals, a Berkeley Heights, NJ-based clinical-stage biopharmaceutical company developing therapies for patients with cardiometabolic conditions, raised up to $287M in Series D1 funding.
Backers included new investors includi... |
| 14.01.2026 | AirNexis Therapeutics Secures $200M for Groundbreaking COPD Treatment AN01 | AirNexis Therapeutics emerged, securing $200 million in Series A funding. This substantial capital infusion targets chronic obstructive pulmonary disease (COPD). The company focuses on developing AN01, a novel dual PDE3/4 inhibitor. AN01 is... |
| 12.01.2026 | AirNexis Therapeutics Raises $200M in Series A Funding | AirNexis Therapeutics, a Palo Alto, CA-based clinical stage biotech company developing therapeutics for pulmonary diseases, raised $200M in Series A funding.
The round was led by Frazier Life Sciences, with participation from OrbiMed, SR On... |
| 12.01.2026 | Haisco Grants Global Rights of Innovative Drug HSK39004 to AirNexis in Deal Exceeding USD 1 Billion | HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilities
BEIJING, Jan. 12, 2026 /PRNewswire/ -- On January 9, 2026, Haisco Pharmaceutical Group Co., Ltd. (Ticke... |
| 11.01.2026 | AirNexis Therapeutics Launches With $200 Million Series A To Advance Phase 2 Dual PDE3/4 Inhibitor AN01 For COPD | AirNexis Therapeutics has launched as a clinical-stage biotechnology company focused on pulmonary diseases, closing a $200 million Series A financing and securing an in-license to a Phase 2 dual PDE3/4 inhibitor for chronic obstructive pulm... |
| 08.01.2026 | Poplar Therapeutics Launched With $50 Million Series A To Advance Anti-IgE Therapy for Multiple Atopic Conditions | Poplar Therapeutics has launched as a clinical-stage immunology company with a $50 million Series A financing to advance PHB-050, a next-generation anti-IgE antibody being developed for food allergy and other atopic conditions such as asthm... |
| 08.01.2026 | Poplar Therapeutics Raises $50M in Series A Funding | Poplar Therapeutics, Inc. (previously known as Phylaxis Bioscience), a Boston, MA-based clinical-stage immunology company, raised $50m in Series A financing.
The round was led by SR One, Vida Ventures and Platanus.
The company intends to us... |
| 27.12.2025 | Addition Therapeutics: $100 Million Funding Raised To Advance All-RNA PRINT Platform For One-Time Genomic Medicines | Addition Therapeutics announced it has raised $100 million in financing to date, highlighting progress toward developing one-time genomic medicines for chronic and rare diseases. Based in South San Francisco, the company is building around ... |
| 17.12.2025 | Addition Therapeutics Raises $100M in Funding | Addition Therapeutics, a San Francisco, CA-based genomic medicine company, raised $100M in funding.
Backers included SR One, Pivotal Life Sciences, Abingworth, Osage University Partners, the Gates Foundation, and BEVC.
The company intends t... |
| 20.10.2025 | Veradermics: $150 Million Series C Raised For Advancing Late-Stage Trials Of VDPHL01 | Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing first-in-class treatments for common dermatologic conditions, has announced the completion of an oversubscribed $150 million Series C financing r... |
| 15.10.2025 | Mission Therapeutics Raises $13.3M in Funding | Mission Therapeutics, a Cambridge, UK-based clinical-stage biotech developing first-in-class therapeutics that promote cell and organ health by enhancing mitophagy, raised $13.3m in funding.
The financing was led by current investors Pfizer... |
| 10.10.2025 | Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan | TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (deve... |
| 03.10.2025 | Avenzo Therapeutics Secures $60 Million Series B to Advance Oncology Breakthroughs | Avenzo Therapeutics secured $60 million in Series B funding. This propels their oncology pipeline. The San Diego biotech now totals $446 million raised. OrbiMed and SR One led the round. New investor Longwood Fund joined. Key existing backe... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 30.09.2025 | Crystalys Therapeutics Raises in $205M Series A Funding | Crystalys Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company, raised $205M in Series A funding.
The round was led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors,... |
| 23.09.2025 | Avenzo: $60 Million Series B Secured For Developing Oncology Therapies | Avenzo Therapeutics, a biotechnology company focused on developing new cancer treatments, has announced the closing of a $60 million Series B funding round. This latest investment follows a previous $386 million raised through its Series A ... |
| 22.09.2025 | Avenzo Therapeutics Raised $60M in Series B Funding | Avenzo Therapeutics, a San Diego, CA-based clinical-stage biotechnology company developing new oncology therapies, raised $60M in Series B funding.
The round was led by OrbiMed and SR One, with participation from new investor Longwood Fund,... |
| 07.09.2025 | Charm Therapeutics Secures $80M for AI-Driven Cancer Battle | Charm Therapeutics, a London-based biotech firm, clinched $80M in Series B funding. This investment fuels its AI-driven drug discovery platform. The company targets precision oncology, focusing on acute myeloid leukemia (AML). Its lead meni... |
| 03.09.2025 | CHARM Therapeutics: $80 Million Series B Raised For Next-Generation AML Treatment | CHARM Therapeutics has closed an oversubscribed Series B funding round, raising a substantial $80 million. This funding will be instrumental in propelling their innovative menin inhibitor into clinical testing. The funding attracted a diver... |
| 02.09.2025 | London’s CHARM Therapeutics raises €68.5 million financing to tackle treatment-resistant cancers | British BioTech startup CHARM Therapeutics, announces closing of an oversubscribed Series B funding round, raising €68.5 million to advance its next generation menin inhibitor into clinical development.
The funding round was co-led by New E... |
| 02.09.2025 | Charm Therapeutics Raises $80M in Series B Financing | Charm Therapeutics, a London, UK-based biotechnology company which specializes in precision oncology treatments, raised $80M in Series B funding.
The round was led by New Enterprise Associates (NEA) and SR One, with participation from exist... |
| 28.05.2025 | FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 Financing | In the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m... |
| 23.05.2025 | FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of Plixorafenib | FORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round |
Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round | EQT Life Sciences invests in Asceneuron, a neurodegeneration therapeutics company, as part of USD 100 million Series C financing round
Tue, Jul 16, 2024 09:15 CET Report this content
EQT Life Sciences has invested in Asceneuron’s oversubscr... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round |
Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 28.03.2023 | USA-based One announces closure of its Second Venture fund at USD 600 million | USA-based transatlantic life sciences investment firm SR One Capital Management announced the closure of its second venture fund. The company closed its fund at USD 600 million, exceeding its target of USD 500 million. SR One announced the ... |
| 11.02.2021 | SR One Adds Venture Partners | SR One, a trans-Atlantic venture capital firm investing in life sciences companies, added Chris Chai and Peter Van Vlasselaer, Ph.D. to Venture Partner role.
Chris Chai, Venture Partner, Capital Markets
Chai comes to SR One from Principia B... |
| 11.02.2021 | SR One Adds Venture Partners | SR One, a trans-Atlantic venture capital firm investing in life sciences companies, added Chris Chai and Peter Van Vlasselaer, Ph.D. to Venture Partner role.
Chris Chai, Venture Partner, Capital Markets
Chai comes to SR One from Principia B... |
| 11.02.2021 | SR One Adds Venture Partners | SR One, a trans-Atlantic venture capital firm investing in life sciences companies, added Chris Chai and Peter Van Vlasselaer, Ph.D. to Venture Partner role.
Chris Chai, Venture Partner, Capital Markets
Chai comes to SR One from Principia B... |
| 27.01.2021 | Narrow River Management Announces Formation and Financing of Two New Companies Developing Therapies for Renal Diseases | NEW YORK (PRWEB) January 27, 2021
Narrow River Management (“Narrow River”) today announced the formation and completion of a Series A financing for two new companies – River 2 Renal Corp. (“R2R”) and River 3 Renal Corp. (“R3R”). Each compan... |
| 24.11.2020 | SR One Closes First Biotech VC Fund, at $500M | SR One, a trans-Atlantic biotech venture capital firm, closed its first independent fund, having recently completed its spinout from GlaxoSmithKline (GSK).
GSK is the largest investor in the $500m fund, joined by a global pool of institutio... |
| 14.01.2019 | Breakdown of biggest VC raises in Midwestern states in 2018 | As the new year gets underway, 2018’s fundraising numbers are rolling in, allowing us to get a snapshot of how the Midwest’s top startups fared. It was a good year for the Midwest, which we define here as Minnesota, Wisconsin, Illinois, Ind... |
| 11.01.2019 | Breakdown of biggest VC raises in Midwestern states in 2018 | As the new year gets underway, 2018’s fundraising numbers are rolling in, allowing us to get a snapshot of how the Midwest’s top startups fared. It was a good year for the Midwest, which we define here as Minnesota, Wisconsin, Illinois, Ind... |
| 11.01.2019 | Breakdown of biggest VC raises in Midwestern states in 2018 | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
As the new year gets underway, 2018’s fundraising... |
| 30.05.2018 | As Propeller Health closes latest fundraise, it expands digital drug delivery ambitions beyond inhalers | Propeller and Aptar initially collaborated in 2016 on an integrated connected metered dose inhaler. They plan to co-market the technologies coming out of the joint venture — Propeller will manage the digital services and Aptar Pharma will m... |
| 28.07.2017 | A race is underway to repair our hearing — with medicine | On any bustling city street, in the middle of the afternoon, it’s probably the case that half or more people are wearing earbuds, while the rest are abiding the noise pollution all around them. No one thinks twice about it, either.
The real... |
| 20.04.2017 | ZappRx Raises $25M for Specialty Pharmaceutical Management Platform | Normal 0 false false false EN-US X-NONE X-NONE
ZappRx, a Boston, MA-based provider of specialty pharmaceutical management platform has raised $25 million in Series B funding led by Qiming US Healthcare Fund. The round includes participation... |
| 20.04.2017 | ZappRx Raises $25M Series B | ZappRx, Inc., a digital health company focused on modernizing and expediting the specialty drug prescribing process, today announced it closed $25 million in Series B funding led by Qiming US Healthcare Fund, a venture capital firm based in... |
| 20.10.2016 | Propeller Health closes Series C round, plans to add more respiratory meds to adherence platform | SR One, the investment arm of GlaxoSmithKline, Hikma Ventures, part of Hikma Pharmaceuticals, and 3M Ventures, all new investors to Propeller Health, took part in the Series C round alongside existing investors Safeguard Scientifics and Soc... |
| 30.06.2016 | Morphic Therapeutic Raises $51.5M Series A Co-Led by SR One and Pfizer Venture | WALTHAM, Mass.--(BUSINESS WIRE)--Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A financing to advance multiple programs into the... |
| 18.12.2015 | Daily funding roundup - December 18, 2015 | Pave secured $300M; Navitor Pharmaceuticals, Inc received $33M; Checkpoint Surgical raised $7.5M
Jolla Ltd., a Finnish mobile company and developer of open mobile operating system Sailfish OS, today announced that it has closed its C invest... |
| 03.12.2015 | Daily funding roundup - Dec. 3, 2015 | True North Therapeutics bagged $40M; Allocadia raised $16.5M; Younity received $8M funding
Younity, an iOS app for streaming media from your Mac, today announced an $8 million Series A round of funding led by venture capital firm Marker LLC... |
| 15.10.2015 | Decibel Therapeutics Launches with $52M Series A Financing | Decibel Therapeutics, a Cambridge, Mass.-based newly formed hearing company focused on discovering and developing new medicines to protect, repair and restore hearing, is being launched with a $52m Series A financing.
The round was led by T... |
| 15.10.2015 | Third Rock hearing loss startup Decibel Therapeutics launches with $52M | Indeed, Third Rock companies generally take this broad scale approach to their respective fields – take Bluebird Bio’s approach to gene therapy, or Constellation Pharmaceuticals’ approach to epigenetics.
Starr, a cofounder at Third Rock, sa... |
| 15.10.2015 | Daily funding roundup - October 15, 2015 | Quip secured $30M; OpenGov raised $25M; Niantic landed $20M
OpenGov, which allows local governments to bring their data to the cloud, has an additional $25 million, it announced on Thursday The oversubscribed funding round included existing... |
| 29.09.2015 | Asceneuron raises CHF 30 million | |
| 30.06.2015 | Clinical decision support startup collaborates with Epic, Allscripts to better connect clinical guidelines and EMRs | In response to emailed questions, Avhana Health CEO and co-founder Noah Weiner explained the company’s challenge. He noted that doctors are required to use electronic medical records and are paid to follow clinical guidelines, but there isn... |
| 30.04.2015 | CRISPR Therapeutics Raises Additional $64 Million | |
| 02.04.2015 | ZappRx Raises $5.6 Million In Series A Funding To Expand The Company | Pharmacy coordination platform ZappRx announced it has raised $5.6 million in Series A funding today. The new financing will go to further build upon ZappRx’s prescription data automation technology and help to scale operations for the star... |
| 02.04.2015 | ZappRX raises $5.6M Series A as pharma becomes more responsive to specialty drug support needs | ZappRx will also work with obesity-focused biopharma company Zafgen (NASDAQ: ZFGN), to support patients with Prader-Willi syndrome — a genetic condition affecting up to 30,000 people — and hypothalamic injury-associated obesity.
Promoted
Th... |
| 29.05.2014 | Puridify Raises £850K in Funding | Puridify, a London, UK-based newly formed company providing purification solutions for biotherapeutic manufacturing, raised £850k in funding.
The round was co-led by Imperial Innovations Group plc (AIM:IVO), the technology commercialization... |
| 24.03.2014 | Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’ | “The biggest challenge for the pharmaceutical company is actually coming up with a product that works,” said Jeffrey Moore, managing partner of Healthcare Venture Management. So other factors like a startup’s executive team become less impo... |
| 30.01.2014 | GSK venture arm makes first health IT investment to speed up specialty pharma orders | ZappRx’s collaborative tool seeks to improve communication among pharmacies, providers and patients. It also helps speed up the process of filling out the 50-page risk evaluation and mitigation strategy or REMS documents. By making it easie... |
| 29.10.2013 | Sigh. Healthcare corporate venture capital investments hit five-quarter low in Q3 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 08.08.2013 | GSK shifts its investment approach | It’s in the process of offering up to 20 exploratory research grants and creating a network of investigators. It wants to integrate a broader research community and is working with other major funding and research organisations interested i... |
| 20.05.2013 | eFFECTOR Therapeutics Completes $45M Series A Financing | eFFECTOR Therapeutics, a San Diego, CA-based newly formed biopharmaceutical company, completed a $45m Series A financing.
Backers included U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage... |
| 20.05.2013 | eFFECTOR Therapeutics Raises $45 Million in Series A Financing | eFFECTOR Therapeutics Raises $45 Million in Series A Financing
Company to Focus on Small Molecule Selective Regulators of Protein Synthesis for Cancer
San Diego, CA – May 20, 2013 – eFFECTOR Therapeutics, a newly established biopharmaceutic... |
| 15.03.2013 | For daily dish from investors, look no further than these 10 VCs on Twitter | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| 12.12.2012 | River Vision Development Completes $17M Series A Financing | River Vision Development Corp., a company that develops a novel protein therapy for the treatment of Graves’ Orbitopathy (GO), completed a $17m Series A financing.
The round was led by SR One and Lundbeckfond Ventures with participation fro... |
| 25.10.2012 | Thrasos Secures $35M |
MONTREAL, QUEBEC, Firm completed a $35M financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI). The round was led by new investor, SR One, with funds coming from the GSK Canada ... |
| 25.10.2012 | Thrasos Therapeutics Completes $35M Financing | Thrasos Therapeutics, a Montreal, QC, Canada-based clinical stage, biotherapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of kidney disease, has completed a $35m financing.
Th... |
| 28.09.2012 | IlluminOss Medical Secures $28M in Series C Venture Capital Financing | IlluminOss Medical, Inc., a East Providence, RI-based developer of photodynamic orthopedic implants, has secured $28m in Series C venture capital financing.
The round was co-led by Tekla Capital Management and Life Sciences Partners, with p... |
| 16.07.2012 | Migraine patch application resubmitted for FDA approval | Jane Hollingsworth, NuPathe’s CEO, said she expects a six-month review by the FDA.
“With the additional data and enhancements made to the patch, we have submitted a strong application and have an even more attractive commercial opportunity ... |
| 09.07.2012 | PsiOxus Therapeutics Closes £22M Series B Equity Financing | PsiOxus Therapeutics, Ltd., an Oxford, UK-based development stage biotechnology company using non-traditional approaches to develop novel therapeutics that address cancer and other clinically unmet diseases, has closed a £22m (approximately... |
| 05.06.2012 | Auxogyn Raises $18M In Series B |
MENLO PARK, CA, Privately-held company advancing women's reproductive health, today announced it raised $18 million through a Series B financing.
>> Click here for more funding data on Auxogyn
>> To export Auxogyn funding da... |
| 05.06.2012 | Auxogyn Raises $18M in Series B Financing | Auxogyn, Inc., a Menlo Park, Calif.-based company advancing women’s reproductive health, has raised $18m in Series B financing.
The round was led by new investor SR One, with participation from Series A investors Kleiner Perkins Caufield an... |
| 18.01.2012 | RaNA Therapeutics Closes $20.7M Series A Financing | RaNA Therapeutics, a Cambridge, Mass.-based company that is developing drugs by modulating disease-associated long non-coding RNA (lncRNA) and restoring normal expression of individual targeted genes, has completed a $20.7m Series A financi... |
| 15.11.2011 | NuPathe to resubmit migraine patch for approval in 2012 | Migraine headaches affect about 31 million adults in the United States. Symptoms include moderate to severe headache pain, nausea and vomiting, photophobia, or abnormal sensitivity to light, and phonophobia, or abnormal sensitivity to sound... |
| 10.11.2011 | GSK’s new $50M life sciences fund to invest in Canadian innovation | “This is an important step in addressing Canada’s innovation gap and we’re excited by the prospect of developing even closer ties with leading research organizations across Canada to enhance opportunities for innovation and create new high-... |
| 26.08.2011 | MISSION Therapeutics Raises £6M in Series A Funding | MISSION Therapeutics Ltd, a Cambridge, UK-based newly formed company that is developing a broad platform of technologies for the discovery and development of targeting enzymes involved in cancer and other diseases, has raised £6m in a Serie... |
| 28.06.2011 | Nimbus Discovery Closes $24M Series A Financing | Nimbus Discovery LLC, a biopharmaceutical company that is applying advances in computer-based drug discovery to develop new medicines against important drug targets, closed a $24m Series A financing.
The round was co-led by Atlas Venture, S... |
| 13.06.2011 | HTG Molecular Diagnostics Receives $500k from SR One in Series D Financing | HTG Molecular Diagnostics, a Tucson, Arizona-based provider of molecular technology solutions, has received a $500k investment from SR One, the corporate venture capital arm of GlaxoSmithKline, in the second tranche of its series D financin... |
| 12.05.2011 | SpringLeaf Therapeutics Closes $15M Series B Financing | SpringLeaf Therapeutics, a Boston, MA-based developer of therapies that combine novel and existing pharmaceuticals with a proprietary self-contained subcutaneous delivery system, has closed a $15m Series B financing.
The round was led by ne... |
| 21.10.2010 | Dicerna Pharmaceuticals Secures Additional $4M in Series B Financing | Dicerna Pharmaceuticals, Inc., a Watertown MA-based second generation RNA interference (RNAi) company developing novel therapeutics, secured an additional $4m in the second closing of its Series B equity financing.
This brings the total cap... |
| 09.07.2010 | Ansaris grabs $1.7M for oncology, immunology drug development | The funding was sourced from Ansaris’ existing investors, which include Prism Venture Partners, HBM BioVentures Ltd., and SR One, the venture arm of GlaxoSmithKline.
“It shows our investors’ confidence in what we’re doing now,” Lau said, th... |
| 07.08.2009 | Friday Q&A: Russell Greig of GlaxoSmithKline’s SR One | Russell Greig has come a long way.
The 57-year-old Scotsman, who still carries that signature and recognizable accent, rode a Fulbright scholarship and a nearly three-decades-long career with pharmaceutical giant GlaxoSmithKline to head SR ... |
| - | ZappRX raises $5.6M Series A as pharma becomes more responsive to specialty drug support needs | ZappRx has raised a Series A round to support sales and product development for its specialty pharmaceutical portal. SR One, the venture arm of GlaxoSmithKline, led the $5.6 million fundraise, along with Atlas Venture. It also added former ... |
| - | Third Rock hearing loss startup Decibel Therapeutics launches with $52M | Third Rock Ventures is launching a startup geared at broadly treating hearing loss – leading a $52 million Series A for freshly christened Decibel Therapeutics.
The Boston company is developing drugs that can be directly injected into the i... |
| - | GSK’s new $50M life sciences fund to invest in Canadian innovation | GlaxoSmithKline (NYSE:GSK) aims to find and nurture life sciences innovation in the Great White North.
GSK today launched a new $50 million fund that will invest in “early stage breakthrough research” in Canada. In addition to committing fu... |
| - | Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’ | It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.”
I’ve often heard VCs and angel investors c... |
| - | Sigh. Healthcare corporate venture capital investments hit five-quarter low in Q3 | Corporate venture capital investments in healthcare hit a five-quarter low in Q3, down in both deals and funding, according to a new report out from CB Insights. Compared to the quarter before, deals and funding decreased by 41 percent and ... |
| - | GSK venture arm makes first health IT investment to speed up specialty pharma orders | Health IT startup ZappRx has raised $1 million as part of a pivot from its e-prescribing platform to focus on automating the cumbersome manual process of ordering specialty pharmaceuticals. ZappRx wants to shorten to a few days a process th... |
